-
公开(公告)号:US20210347768A1
公开(公告)日:2021-11-11
申请号:US17121165
申请日:2020-12-14
申请人: Valo Health, Inc.
发明人: Brian Raimundo , Elena S. Koltun , John Griffin , Eric Stangeland
IPC分类号: C07D417/12 , C07D401/12 , C07D275/06 , A61P1/16 , A61P25/28 , A61P3/10 , A61P3/08 , A61P29/00 , C07D417/14
摘要: Provided herein are compounds, compositions including them, and methods of modulating GPR120 activity and treating diseases mediated by GPR120 by administering such compounds and compositions.
-
公开(公告)号:US20200277256A1
公开(公告)日:2020-09-03
申请号:US16656284
申请日:2019-10-17
发明人: William G. Kerr , John D. Chisholm
IPC分类号: C07C309/47 , C07D241/04 , C07D243/08 , C07D487/10 , C07D471/10 , C07D275/06 , A61P35/00
摘要: The present disclosure provides compositions that inhibit the SH2-containing inositol 5′-phosphatase (SHIP), as well as methods using such compositions for use in treating or ameliorating the effects of a medical condition in a subject.
-
公开(公告)号:US10513523B2
公开(公告)日:2019-12-24
申请号:US15569273
申请日:2016-04-28
IPC分类号: C07D487/04 , A61P25/00 , C07D231/54 , C07D235/04 , C07D239/80 , C07D249/18 , C07D275/06 , C07D277/62
摘要: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).
-
4.
公开(公告)号:US10301256B2
公开(公告)日:2019-05-28
申请号:US15363610
申请日:2016-11-29
IPC分类号: C07D275/06 , C07D275/02 , C07C311/06 , C07C311/29 , C07C311/48 , C07C313/06 , C07C311/04 , C07C311/09 , C07C311/17
摘要: The present invention provides compounds and pharmaceutical compositions for treating neurological diseases such as multiple sclerosis.
-
公开(公告)号:US20190002419A1
公开(公告)日:2019-01-03
申请号:US16066971
申请日:2016-12-28
IPC分类号: C07D275/06
摘要: A process for preparing, 1,1,3-Trioxo-1,2-benzothiazole-6-carboxamide of formula (I) comprising: reacting 2-chloro-sulfonyl-terephthalic acid dialkyl ester of formula (II) with ammonia (N H3) or ammonium containing-salt; wherein R represents a branched or non-branched C1-C12 alkyl.
-
公开(公告)号:US20180362543A1
公开(公告)日:2018-12-20
申请号:US16110697
申请日:2018-08-23
申请人: Shionogi & Co., Ltd.
发明人: Kenji TOMITA , Yoshiyuki TAODA , Tsutomu IWAKI , Takashi KAWASUJI , Toshiyuki AKIYAMA , Shuichi SUGIYAMA , Yoshinori TAMURA , Masafumi IWATSU
IPC分类号: C07D498/06 , C07D285/36 , C07D405/14 , C07D243/04 , C07D491/06 , C07D221/18 , C07D291/08 , C07D225/08 , C07D279/02 , C07D209/80 , C07D243/12 , C07D405/04 , C07D237/36 , C07D513/06 , C07D243/38 , C07D267/20 , C07D223/18 , C07D335/10 , C07D471/10 , C07D498/04 , C07D413/04 , C07D241/44 , C07D409/04 , C07D221/12 , C07D471/04 , C07D281/02 , C07D265/34 , C07D275/06 , C07D491/056 , C07D273/01 , C07D495/14 , C07D495/04 , C07D487/04 , C07D513/04 , C07D401/04 , C07D471/06 , C07D311/80
摘要: The present invention provides a novel compound having an antiviral activity, in particular, an HIV replication inhibiting activity, as well as a pharmaceutical composition, in particular, an anti-HIV agent. wherein ring A is substituted or unsubstituted carbocycle or substituted or unsubstituted heterocycle; R1 is substituted or unsubstituted alkyl etc.; R2 is substituted or unsubstituted alkyloxy etc.; n is 1 or 2; R3 is substituted or unsubstituted carbocyclyl or substituted or unsubstituted heterocyclyl; R4 is a hydrogen atom etc.; R6 is substituted or unsubstituted alkyl etc.
-
公开(公告)号:US20180325870A1
公开(公告)日:2018-11-15
申请号:US15616358
申请日:2017-06-07
发明人: HENRY J. BRESLIN , CHAOZHONG CAI , WEI HE , ROBERT W. KAVASH
IPC分类号: A61K31/4164 , A61K9/28 , A61K9/20 , C07D275/06 , A61K31/4174 , C07D233/64
CPC分类号: A61K31/4164 , A61K9/20 , A61K9/2806 , A61K31/4174 , C07D233/64 , C07D275/06
摘要: The present invention is directed to novel opioid receptor modulators of Formula (I). The invention further relates to methods for preparing such compounds, pharmaceutical compositions containing them, and their use in the treatment of disorders that may be ameliorated or treated by the modulation of opioid receptors.
-
公开(公告)号:US20180118751A1
公开(公告)日:2018-05-03
申请号:US15569273
申请日:2016-04-28
IPC分类号: C07D487/04 , C07D235/04 , C07D239/80 , C07D231/54 , C07D249/18 , C07D277/62 , C07D275/06 , A61P25/00
摘要: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions, comprising compounds of Formula (I), and methods of using compounds of Formula (I).
-
公开(公告)号:US09884857B2
公开(公告)日:2018-02-06
申请号:US14906974
申请日:2014-07-22
申请人: BASF SE
发明人: Andreas Hafner , Fritz Blatter , Martin Szelagiewicz , Bernd Siebenhaar , Tiziana Chiodo , Tobias Hintermann , Beate Salvador , Marcus Vossen
IPC分类号: C07D417/12 , C07D275/06 , C07D213/80 , C07C55/12
CPC分类号: C07D417/12 , C07C55/12 , C07D213/80 , C07D275/06
摘要: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.
-
10.
公开(公告)号:US20170362182A1
公开(公告)日:2017-12-21
申请号:US15639223
申请日:2017-06-30
IPC分类号: C07D223/26 , A61K9/16 , C07D213/82 , C07D213/79 , C07D213/69 , C07D213/22 , C07D213/06 , C07C317/04 , C07C233/75 , C07C233/25 , C07C233/03 , C07C205/57 , C07C69/157 , C07C63/307 , C07C61/135 , C07C57/58 , C07C57/30 , C07C53/124 , C07C53/08 , C07C53/02 , C07C51/43 , C07C51/41 , C07C47/544 , A61K47/32 , A61K47/10 , A61K31/616 , A61K31/55 , A61K31/4166 , A61K31/192 , A61K31/167 , C07D233/74 , C07D275/06
CPC分类号: C07D223/26 , A61K9/1652 , A61K31/167 , A61K31/192 , A61K31/4166 , A61K31/55 , A61K31/616 , A61K47/10 , A61K47/32 , C07C47/544 , C07C51/412 , C07C51/43 , C07C53/02 , C07C53/08 , C07C53/124 , C07C57/30 , C07C57/58 , C07C61/135 , C07C63/307 , C07C69/157 , C07C205/57 , C07C233/03 , C07C233/25 , C07C233/75 , C07C317/04 , C07D213/06 , C07D213/22 , C07D213/69 , C07D213/79 , C07D213/82 , C07D233/74 , C07D275/06 , C07C53/06 , C07C53/10
摘要: The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.
-
-
-
-
-
-
-
-
-